GSK · story · 25 October – 26 October
GSK · 4 headlines from 3 outlets, from 25 October 2026 to 26 October 2026.
At ESMO26, GSK has shared data on mo-rez in ovarian cancer.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Pharmaphorum is the largest at 8.3, ahead of AD HOC NEWS (7.7). Pharmaceutical Technology is the smallest at 3.0.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| AD HOC NEWS | 7.7 |
| pharmaphorum | 8.3 |
| Pharmaceutical Technology | 3.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| AD HOC NEWS | 2 | +7.7 |
| pharmaphorum | 1 | +8.3 |
| Pharmaceutical Technology | 1 | +3.0 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +8.7 | Reports strong 76 percent complete response data for GSK. |
| +3.0 | Covers GSK's ovarian cancer ADC at ESMO; competitive field tempers optimism. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +8.3 | Growing evidence for mo-rez in ovarian cancer. |
| +6.7 | Mo-Rez ovarian data reported, with share price mention. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.